Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung cancers; yet the durability of response is limited by drug resistance.
3.Mok TSK, Kim S-W, Wu Y-L, et al. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall surv...
参考文献: Li Y ,et al.,Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature. Mol Clin Oncol. 2017 Aug;7(2):173-182 ...
1. Dearden S, Stevens J, Wu YL, et al. Mutation incidence and coincidence in non small-cell lung cancer: metaanalyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24:2371-6. 2. Koivunen JP, Mermel C...
Haratani K, Hayashi H, Tanaka T, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol, 2017, 28(7): 1532-1539. doi: 10.1093/annonc/mdx183 ...
3.Mok TSK, Kim S-W, Wu Y-L, et al. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses.J Clin Oncol. 2017;35(36):4027-4034. ...
ALK-positive lung cancer: a moving target Article16 February 2023 Introduction Anaplastic lymphoma kinase (ALK) gene alterations are gaining more attention as pan-cancer markers in both solid and hematological malignancies. ActivatingALKalterations (mutations, amplifications, fusions/rearrangements) are foun...
5、Soda M, Choi Y L, Enomoto M, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007, 448(7153): 561-566.6、Camidge D R, Bang Y J, Kwak E L, et al. Activity and safety of crizotinib in patients with ALK-positive non-...
Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study[J]. Thoracic Cancer, 2019, 10(7): 1521-1532. 4、Shimizu J, Masago K, Saito H, et al. ...
Haratani K, Hayashi H, Tanaka T, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. ...